SLC12A8 and cancer: In vitro, siRNA-mediated knockdown of SLC12A8 or treatment with the TLR pathway inhibitor GIT27 was used to assess the effects on the TLR pathway, CD8<sup>+</sup> T cell function (as indicated by PD-1, PRF1, and GZMB expression), and cancer cell invasion via Western blot, immunofluorescence, qPCR, and Transwell assays.